I agree. Like you, I heard it as Yuman saying that they would
. I doubt they will announce just lodging the submission.
A week or two ago someone raised the issue of Paul Hopper's bonus shares which he will only receive on condition that the IND is granted, but which the ASX listing rules say must happen by 30 June. My comment was - I expect them to make that deadline. Based on today's presentation they certainly intend to get the submission in very very soon and they seem entirely confident about the result.
Along with others here I was struck by the absolute conviction of our CEO that the CD19 variant of CF33 will be a whole new paradigm in cancer treatment. Yesterday her adjective was "revolutionary." Today it is "Monumental." @Owl vs Fox , With your medical background and experience I know you will have seen this far more clearly than I did at first. It took me a while to get it, but now I do.
As you will have already known, and as Leslie has explained several times now, the current commercial CD19 CAR T therapies have a 60% - 90% cure rate for blood borne cancers and they have revolutionised treatment and outcomes for that category of cancer. They dominate that market. However blood borne cancers are only 10% of all cancer. Solid tumours are
90% of all cancer, and CAR T has not worked with them.
Now CD19 in combo with a CAR T
looks as though it can achieve the same result in all solid tumours - no matter what kind. If that is proven in clinical studies, and Imugene has a treatment which produces a 60% - 90% cure rate for any solid tumour (or even if it is a bit less than that) - they will simply dominate 90% of the cancer therapy market - along with the CAR T Pharma companies they will partner with.
It's really only sinking in for me now.
If CD-19 is successful - it will make Her-vaxx (and Herceptin) into a niche product, for use by the minority of patients with Her-2 + cancers who have not responded to CD19 plus CAR T. (though possibly PD1-vaxx could be used in combination with the CD19/CAR T).
Leslie's reaction to the inevitable question on partnerships or buy out was equally inevitable. She would not discuss that at all.
However..... she is previously on record as saying that partnership is "the trajectory we are on," and she has also, a year ago, been quoted in the media as saying that partnership is her goal.
So when she she said today that the issue of partnerships was just "too commercially sensitive to discuss," and would not say anything at all about it - not even that partnership is her goal - my interpretation of her comment is that partnerships are now in active negotiation.
We will see "in due course," as they say.
My overall impression: Huge confidence by all speakers. If their confidence is backed up by results, Imugene's partnership with City of Hope will literally transform cancer treatment forever and Yuman Fong and team will be Nobel Prize winners for Medicine.
It really could be that good.
The fun part - we still have excellent chances of Her-vaxx and PD1-vaxx making Imugene into a multi-billion dollar company before we even get the outcome with CF33 and the CD-19 variant.
It could be the ultimate free ride scenario:
Her-vaxx and/or PD1-vaxx generate multi-billion dollar deals for Imugene in the near to mid term and we all triple our money from current SP levels or better.
A bit later on, if CF33/CD-19 then fails - no problem for those who bought now! We will have bought in ahead of any CD19 boosted SP and we will have already tripled our money (or much better)!!!
However
if CF33/CD-19 really does succeed then it will totally eclipse Her-vaxx and PD1-vaxx, greatly reducing their revenue producing potential.
Imugene will have killed it's own babies but - ! hooray ! - it will have done so by developing the immuno-oncology drug of the century and saving countless lives, making Imugene a household name in the process and generating revenue of astonishing proportions.
What ride it has been already.
And the view ahead?
Mesmerising.
Cheers
Dave
(20min delay)